Printed as of 3/28/2024

### **Disclosures**

#### Personal Commercial (9)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Astra Zeneca	Consultant Fees/Honoraria	Modest (< \$5,000)	Other
Bristol Meyers Squibb	Consultant Fees/Honoraria	Modest (< \$5,000)	Other
Corvia	Other - I direct a research echo core lab.My staff performs blinded echo quantitation. I do not receive direct salary support. I am not part of steering committee meetings. I am not a co-author of publications.	None (\$0)	Noninvasive Imaging
Impulse Dynamics	Other - I direct a research echo core lab.My staff performs blinded echo quantitation. I do not receive direct salary support. I am not part of steering committee meetings. I am not a co-author of publications.	None (\$0)	Noninvasive Imaging
Medscape	Consultant Fees/Honoraria	Modest (< \$5,000)	Other
Pfizer	Research/Research Grants	Significant (>= \$5,000)	Other
Pfizer Myovant	Consultant Fees/Honoraria	Modest (< \$5,000)	Other
Roche	Speaker's Bureau	Modest (< \$5,000)	Other
Uptodate	Other - I authored a chapter for uptodate approximately 4 years ago and there is a very modest honorarium.	Modest (< \$5,000)	Other

# Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (6)

Non-Commercial Enity Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
American College of Cardiology	Other - Editor-in-Chief, JACC: CardioOncology	Significant (>= \$5,000)	Other
American Heart Association	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
National Institutes of Health	Research/Research Grants	Significant (>= \$5,000)	
Patient Centered Outcomes Research Institute	Research/Research Grants	Significant (>= \$5,000)	Other
Public Health Institute	Research/Research Grants	Significant (>= \$5,000)	Other
UpToDate	Other - Content Development	Modest (< \$5,000)	Other

### Clinical Trial Enroller (0)

No disclosures on record

## Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

### **Agreement**

Confidentiality, Disclosure and Assignment Agreement | Signed on 4/11/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

**Embargo** | Signed on 4/11/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 8/21/2023

#### **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.